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We investigatedwhether residual material from diagnostic smears of fine needle aspirations (FNAs) ofmammographi-
cally detected breast lesions can be successfully used to extract RNA for reliable gene expression analysis. Twenty-
eight patients underwent FNA of breast lesions under ultrasonographic guidance. After smearing slides for cytology,
residual cellswere rinsedwithTRIzol to recoverRNA.RNAyield ranged from0.78 to88.40μgper sample. FNA leftovers
from 23 nonpalpable breast cancers were selected for gene expression profiling using oligonucleotide microarrays.
Clusters generated by global expression profiles partitioned samples in well-distinguished subgroups that overlapped
with clusters obtained using “biologic scores” (cytohistologic variables) and differed from clusters based on “technical
scores” (RNA/complementary RNA/microarray quality). Microarray profiling used to measure the grade of differentia-
tion and estrogen receptor and ERBB2/HER2 status reflected the results obtained by histology and immunohisto-
chemistry. Given that proliferative status in the FNA material is not always assessable, we designed and performed
on FNA leftover a multiprobe genomic signature for proliferation genes that strongly correlated with the Ki67 index
examined on histologic material. These findings show that cells residual to cytologic smears of FNA are suitable for
obtaining high-quality RNA for high-throughput analysis even when taken from small nonpalpable breast lesions.
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Mammography-based screening programs have dramatically reduced
the size of breast cancers at diagnosis. If on one hand histopathologic
diagnosis with pTNM staging is essential for management of patients
with neoplastic disease, on the other, pathologists are being con-
fronted with increasing demands, from both clinicians and patients,
to provide immunophenotypic and gene expression data for planning
personalized therapy [1]. The smaller the size of the lesion, the more
limited will be the sampling of the specimens. In these terms, small
nonpalpable breast cancers may not be suitable for adequate sampling
necessary for molecular analysis. A common problem related to the
small size of many breast tumors is that, after core needle biopsies
are performed (for cancer diagnosis and immunohistochemistry),
minimal or no tumoral tissue remains in the surgical specimen that
follows. Many of the RNA molecular studies concerning genetic pro-
files of tumors are done from fresh tumoral tissue extracted from the
surgical specimen (once the diagnosis of cancer is established) and
sometimes there remains none. In addition, we also need to take into
account that the accuracy of molecular tests is utterly dependent on
careful preservation of biologic samples before analysis and then on an
adequate sampling of fresh tissues. Different studies [2,3] have dem-
onstrated that substantial RNA degradation may occur during the so-
called “cold ischemia time” that refers to the time of transfer from the
operation room (or removal of blood supply) to the pathology labo-
ratory. Moreover, surgical manipulation may cause changes in gene
expression and thus obscure measures of treatment effects or disease
prognosis [4]. An alternative can be to obtain RNA for profiling from
fine needle aspiration (FNA) cytology and from core needle biopsies
(CNB) [5–12]. Nevertheless, most of the studies were designed to
perform dedicated FNA for routine cytologic diagnosis and then
either single or multiple FNAs dedicated for RNA extraction and
microarray analyses [5–8,10,11]. To our knowledge, only one work
describes RNA extraction from unused residual cells after conven-
tional diagnostic procedures [13] (Table 1). Alternatively, FNAs were
performed on surgically excised specimens or on xenograft [6,9].
Another study describes immediate cryopreservation of FNA cellular
material in RNAlater as a good alternative for obtaining later both
RNA and cytospin slides after thawing [14].
In the standard protocol followed at our institute for FNA of breast
lesions, the aspirated material is immediately smeared onto the slides
and then both needle and syringe are discarded although they retain
residual cancer cells. Occasionally, the leftover may be harvested after
washing the syringe with a fixative and processed for embedding in a
paraffin block for later use for immunophenotyping, particularly for
the evaluation of hormone receptor, proliferation index by Ki67, and
HER2 expression by immunocytochemistry. However, in our experi-
ence, the reliability of immunocytochemical results, particularly of
Ki67, can be limited by the hypocellularity of the samples. We consid-
ered that although the FNA leftover is not of interest to the pathologist
for the onsite diagnosis, it may be an important additional source of
fresh cell material, suitable for banking and for assessing prognostic
and predictive factors in the preoperative setting using molecular tests.
This is of particular significance when dealing with small nonpalpable
tumors that represent a high rate of screen-detected lesions, where fresh
tissue banking for molecular analysis is impossible.
The aim of this study was to validate the possible use of RNA
extracted from cells residual to diagnostic smears obtained from
FNA of small nonpalpable breast lesions as an adequate and reliable
material for gene expression analysis.Materials and Methods
Sample Collection
The design of the study illustrated in Figure 1 was approved by
the institutional review board of the Breast Unit of the Azienda
Ospedaliero-Universitaria San Giovanni Battista di Torino and by the
ethic institutional review board for “Biobanking and use of human tis-
sue for experimental studies” of the Department of Human Oncology
and Biomedical Science of the University of Torino. The cytology left-
overs were collected from 28 diagnostic FNA samples performed in the
Radiology Department of San Giovanni Battista Hospital, Turin, from
June to July 2010 on mammographically detected opacities. Patients
were informed of the study protocol and that it would not interfere
with diagnosis or treatment decisions.
All FNAs were performed under ultrasound guidance by an expe-
rienced breast radiologist using a 22-gauge needle attached to a syringe
inserted into a pistol grip holder. The samples were processed using a
standard protocol for FNA diagnosis. The aspirated material was
smeared onto two slides; the first one was immediately fixed in meth-
anol for 5 minutes and then stained with hematoxylin and eosin. The
second slide was air-dried for Giemsa staining. One milliliter of TRIzol
(Invitrogen, Carlsbad, CA) solution was then aspirated with the needle,
and after rinsing the syringe, the solution containing the residual
material was transferred to a vial and stored on ice. At the end of the
FNA session, the vials were transported in ice to the cytology laboratory
and stored at −80°C for up to 1 month. An experienced cytopathologist
was present onsite to assess the adequacy of the FNA and if the hema-
toxylin and eosin smear was not suitable for diagnostic purposes, the
patient underwent a second FNA. A core biopsy was immediately per-
formed after the FNA, in case of discrepancy between the radiologic
risk and the cytologic diagnosis.
For each FNA, the cytologic category “C” proposed by the European
Guidelines for breast screening pathology [15] was given to classify the
smears together with the final diagnosis (Table 2). Because it is possible
that no cellular material remains in the syringe after the preparation of
diagnostic smears, we compared the amount of RNA with the smear
cellularity to evaluate whether this morphologic parameter could be
used for the assessment of adequacy of the leftover. Thus, for the study
purposes, cellularity was evaluated independently by two pathologists
(A.S. and I.C.) at low magnification (4×), and when cells (including
cancer, stromal, and inflammatory cells) were present in less than
one third, from one third to two thirds, and more than two thirds of
the smear, they were classified as having “low,” “intermediate,” or
“high” cellularity, respectively. The prevalence of normal epithelial,
cancer, stromal, and inflammatory cells (lymphocytes vs granulocytes)
was carefully detailed (Table 2). Nuclear grade was given for neoplastic
smears using the criteria proposed by Dabbs and Silverman [16]. In
low-nuclear-grade cancers, most of the neoplastic nuclei were small
and uniform with smooth membranes and showed fine chromatin
and no nucleoli; intermediate-grade nuclei were shown to be up to twice
the size of those of low nuclear grade, with moderate pleomorphism, and
small nucleoli. High-nuclear-grade specimens showed marked pleomor-
phism and hyperchromatism and macronucleoli. Lesion size was
recorded for each case (Table 2).RNA Extraction
RNA extraction was performed by rinsing the FNA syringe with 1ml
of TRIzol reagent, according to the manufacturers’ instructions. RNA
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Figure 1. Study flowchart. Flowchart illustrating the design of
the study.
Translational Oncology Vol. 5, No. 3, 2012 Using FNA Leftover as a Source of RNA Annaratone et al. 183pellets were dissolved in a final volume of 35 μl of diethylpyrocarbonate
water, left on ice for 1 hour, and then heated to 60°C for 10 minutes.
RNA concentration was assessed using a spectrophotometer (Bio-
Photomer Eppendorf AG, Hamburg, Germany), and then the dis-
tribution of the amount of total RNA (μg) extracted was evaluated.
The quality and quantity of the extracted RNA were also assessed
using a Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA)
based on a 28S/18S ribosomal RNA ratio and on the “RNA integrity
number” (RIN).Reverse Transcriptase–Polymerase Chain Reaction and
Polymerase Chain Reaction Analysis
Reverse transcriptase–polymerase chain reaction (RT-PCR) was
performed after a DNAse treatment step with TURBO DNA-free
Kit (Ambion, Foster City, CA). For each sample, up to 4 μg of
RNA was reverse transcribed to complementary DNA (cDNA) with
the High-Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems, Foster City, CA). RNA samples without reverse transcriptase
were reverse transcribed as negative controls of DNA contamination
for PCR analyses. Messenger RNA (mRNA) for PGK (PGK1,
NM_000291.3) was amplified for each sample for quality control of
RNA integrity and absence of DNA polymerase inhibitors (forward,
5′-CAgTTTggAgCTCCTggAAg-3′; reverse, 5′-TgCAAATCCA
gggTgCAgTg-3′). The PGK gene was amplified with a touchdownPCR program [17]. cDNA samples were subsequently amplified for
the target sequences by using published primers for CK19 (KRT19,
NM_002276.4) [18]. Each PCR was carried out with a mix containing
PCR Buffer 10× (1× final), MgCl2 (2 mM final) POLYTAQ Taq
DNA Polymerase (1.5 U final; Polymed, Florence, Italy), dNTPs mix
(0.2 mM final), cDNA (200-250 ng), and primers. The reactions
were performed on PTC-100 Peltier Thermal Cycler (MJ Research,
Inc, Waltham, MA). PCR products were separated by electrophoresis
on an agarose gel stained with ethidium bromide. To reduce the risk
of contamination from previously amplified products, separate bench
areas were used for RNA isolation, amplification, and electrophoresis.Microarray Data Generation and Analysis
Biotinylated complementary RNA (cRNA) was prepared using the
Illumina TotalPrep RNA Amplification Kit (Ambion, Inc, Austin,
TX) according to the manufacturer’s recommendations starting with
500 ng of total RNA or, when less RNA was available, with lower
amounts down to a minimum of 90 ng. Hybridization of the cRNA
to the HumanHT-12_V3 Expression BeadChip (Illumina, Inc, San
Diego, CA), washing, and scanning were performed according to the
Illumina BeadStation 500× manual (revision C). Microarray data
were cubic-spline-normalized with the GenomeStudio software (Illu-
mina) and subsequently processed and analyzed using Excel (Micro-
soft Corp, Redmond, WA). Data were clustered and visualized using
the GEDAS software [19]. Bootstrap cluster analysis was performed
using the “pvclust” R package [20,21]. Microarray expression data are
deposited in Gene Expression Omnibus (GEO accession number
GSE22495). Additional details on in silico analysis of gene expression
and classification of FNA leftover samples are provided in the Supple-
mentary Methods. Statistical power analyses were performed using
two online tools: http://www.quantitativeskills.com/sisa/statistics/
correl.htm and http://www.dssresearch.com/KnowledgeCenter/
toolkitcalculators/statisticalpowercalculators.aspx.Results
Smear Cellularity, RNA Yield, and RT-PCR Efficiency
As shown in Table 2, total RNA was successfully extracted from all
the 28 FNA samples and the mean RNA yield per FNA was 11.7 μg
(range, 0.78-88.4 μg; median, 4.85 μg; mode, 7.5 μg).
We then compared the size of the lesions with the amount of
RNA yield. The opacities ranged in size from very small and non-
palpable (5 mm, sample 23W) to large palpable lesions (used as
control). One case was large enough to be suitable for primary systemic
therapy (70 mm, sample 19S). However, even in very small malignant
(samples 3C, 4D, and 23W) and in nonmalignant lesions (samples 10J
and 28AB), the RNA yield was adequate (Table 2).
Afterward, the cellularity of the smears (classified as high, inter-
mediate, and low) was compared with the amount of RNA extracted
from the leftover because it was possible that no cellular material
remained in the needle after the preparation of diagnostic smears.
As shown in Figure 2A, the amount of total RNA (μg) extracted
from FNA leftovers correlated well with the amount of cells present
on the smear. Regarding the cell type, all the smears displayed a
prevalence of epithelial cells (either benign or malignant depending
on the nature of the lesion itself ), followed by elongated stromal
184 Using FNA Leftover as a Source of RNA Annaratone et al. Translational Oncology Vol. 5, No. 3, 2012cells or small fragments of connective tissue. Inflammatory cells
(lymphocytes or granulocytes) were rare compared with the other
cell populations. In five samples, only cancer cells were detected
(Table 2).
RNA integrity and absence of DNA polymerase inhibitors were
then assessed by the percentage of samples positive for PGK house-
keeping gene. Of 28 samples, 26 (92.8%) were RT-PCR positive for
PGK (the negative samples were 1A [lobular breast carcinoma] and
24X [ductal invasive carcinoma with sclerosis]). These 26 samples
were tested for CK19 gene expression, a low-molecular-weight cyto-
keratin specific for normal and neoplastic breast epithelium. All of
them were positive, with the exception of that composed of few
apocrine cells (sample 28AB), confirming efficient detection of epi-
thelial cells by PCR (Figure 2B).Figure 2. RNA yield and RT-PCR efficiency in FNA leftovers. (A) Dis-
tribution of total RNA yield from FNA leftovers. The amount of total
RNA micrograms extracted (y axis) from FNA leftovers was sub-
divided in three classes of sample cellularity, namely, high, inter-
mediate, and low, as indicated on the x axis. (B) RT-PCR analysis
of PGK and CK-19 in FNA leftovers. Lanes 1 and 2, FNA samples.
Lane C+, positive control. Lane C−, negative control.Analysis of Global Gene Expression Profile
This analysis was performed on 23 of 24 leftover samples classified
cytologically as malignant (C5). For these cases, the corresponding
histologic specimens were retrieved and reanalyzed for routine prognos-
tic factors (histologic grade, estrogen receptor [ER] expression, proges-
terone receptor [PgR] expression, proliferation index as determined by
Ki67 [%], and HER2 expression). One case was not analyzed because
the surgical histologic samples were not available. In addition, lab-on-
chip analysis of the FNA leftover with the Bioanalyzer 2100 (Agilent)
allowed measuring RNA quality in RIN values (Materials and Meth-
ods), which ranged from 4.4 to 8.8 (median, 7.3). RIN values of at leastTable 2. Characteristics of the 28 Samples of FNA Cytology.No. Sample Mammographic Size (mm) RNA Yield (μg) Cellularity Cell Types on Smears Cytological CategoryCancer Stromal Inflammatory1 A 10 1.30 L 80% 20% C5
2 B 12 4.16 L 70% 30% C5
3 C 8 5.20 I 60% 35% 5% C5
4 D 7 7.80 L 100% C5
5 E 13 8.06 H 80% 15% 5% C5
6 F 13 9.36 H 100% C5
7 G 15 10.50 I 60% 30% 10% C5
8 H 10 11.44 H 90% 10% C5
9 I 18 12.74 I 90% 10% C5
10 J 8 2.70 L * 10% C3
11 K 10 7.50 I 50% 50% C5
12 L 13 17.16 I 75% 20% 5% C5
13 M 14 26.26 H 100% C5
14 N 12 68.10 H 70% 10% 20% C5
15 O 11 88.40 H 60% 10% 30% C5
16 P 10 4.50 I 70% 30% C5
17 Q 12 5.98 L 75% 5% 20% C5
18 R 29 7.50 H 70% 5% 25% C5
19 S 70† 3.30 L 75% 20% 5% C5
20 T 13 2.10 H 80% 15% 5% C5
21 U 10 1.80 L 100% C5
22 V 10 2.08 I 45% 50% 5% C5
23 W 5 3.64 L 85% 10% 5% C5
24 X 10 0.78 I 90% 10% C5
25 Y 15 4.16 H 85% 5% 10% C5
26 Z 11 3.64 L 100% C5
27 AA 10 2.60 I 80% 10% 10% C5
28 AB 7 3.90 L * C2C2 indicates benign; C3, probably benign; C5, malignant; I, intermediate; H, high; L, low.
*One hundred percent of nonneoplastic apocrine cells.
†The patient received neoadjuvant chemotherapy before surgery.
Figure 3. Technical quality controls. For each FNA sample, the following five technical quality control parameters are displayed, from top
to bottom as indicated: (top) RIN number measured with the bioanalyzer on the extracted total RNA, RNA yield as measured with the
spectrophotometer, cRNA yield as measured with the Bioanalyzer, total number of genes with detection P value of 0 after hybridization,
and (bottom) average signal on the microarray.
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with Illumina arrays, reasonable quality data can be obtained also with
samples with lower RIN values (our unpublished observations). There-
fore, all the 23 RNA samples were processed for microarray analysis.
After reverse transcription and in vitro transcription, the amount of
cRNA obtained was quantified using spectrophotometer to check
that sufficient cRNA was generated also when it was not possible to
start from 500 ng of RNA. Finally, we considered two posthybridiza-
tion microarray quality control parameters: (i) number of detected
genes and (ii) average signal; the values obtained from leftovers of
FNA were compared to those previously obtained on fully intact
RNA from four breast cancer fresh-frozen samples [23]. All the
above-mentioned quality control parameters were plotted together to
assess possible relationships, as illustrated in Figure 3. No major differ-
ences were observed in any parameter between FNA leftovers and fresh-
frozen sample. Notably, the RIN number showed no correlation with
any other technical parameter: even samples with low RIN values
yielded good amounts of cRNA, high numbers of detected genes,
and a strong signal. As expected, a high correlation was observed be-
tween the number of detected genes and the average signal (Pearson =
0.89) and also between the initial RNA yield and the cRNA yield(Pearson = 0.81). A lower but still significant correlation was observed
between cRNA yield and both the number of detected genes and the
average signal (Pearson = 0.44 and 0.36, respectively). These results
confirmed that, at least for the Illumina platform and procedures,
microarray data of technically good quality can be obtained from most
FNA leftover samples.
We then proceeded by exploring in a quantitative manner if gene
expression profiling highlights biologic features of the leftover sam-
ples rather than technical features associated with their preparation.
We defined a set of numerical scores, each ranging from −3 to +3
and representing a biologic or technical variable, as illustrated in
Table 3.
FNA leftovers were hierarchically clustered using Pearson correla-
tion with complete linkage, based on the whole set of expressed genes
(i.e., genes for which the GenomeStudio detection P value was 0 in
at least two samples). The statistical robustness of the clusters was
evaluated by a bootstrapping procedure [20]. As illustrated in Fig-
ure 4, FNA samples were clustered in three major branches, with
reasonable consistency also in bootstrapped data (bootstrap probabil-
ity of 77%, 97%, and 100%). The heat map below the clustering
tree represents three categories of variables, respectively, from top
186 Using FNA Leftover as a Source of RNA Annaratone et al. Translational Oncology Vol. 5, No. 3, 2012to bottom: 1) cytologic parameters of the FNA samples, 2) histopath-
ologic parameters of the corresponding surgical samples, and 3) tech-
nical parameters associated to RNA expression profiling. It seems
evident that biologic variables of FNA samples and derived surgical
samples are more sharply partitioned by the expression-based clusters
than by technical variables. In particular, the leftmost cluster is
enriched in triple-negative, aggressive cancers, whereas the rightmost
cluster is enriched in less aggressive, ER-positive tumors. The three
cancers of special histologic type (endocrine, papillary, and lobularFigure 4. Hierarchical clustering of FNA leftover samples based on
annotated with the probability value calculated by the pvclust tool on
sample, three categories of variables measured, respectively, on FN
and RNA and microarrays (bottom, five rows).carcinomas, respectively, corresponding to samples F, M, and Q)
were in the same central cluster, as expected by their biology. These
results show that gene expression profiling partitions FNA leftover
samples based on their biologic properties rather than on the quality/
amount of RNA/cRNA obtained.Classification of FNA Samples by Expression Profiling
We then investigated the possibility of using microarray analysis to
define grade and ER, ERBB2/HER2 and Ki67 status directly on
FNA leftovers. For this purpose, histologic grade and ER, ERBB2/
HER2, and Ki67 immunohistochemical (IHC) data were available as
a reference from surgical specimens of all the 23 profiled samples
(Table W1).
To assess ER and ERBB2 status, we used single probes of the Illu-
mina array. According to the ENSEMBL genome database (http://
www.ensembl.org), these probes match equivalent Affymetrix probe
sets previously found to correctly define ER and ERBB2 status of
breast cancer samples [24] and further validated by us on large cohorts
assembled from published Affymetrix data sets (Figures W1 and
W2). As displayed in Figure 5, A and B, Illumina probes in our left-
over data set were very good at partitioning samples: no single ER-
negative sample had an ESR1 probe signal higher than the lowest
ER-positive sample. Similarly, no ERBB2-positive sample (IHC score
3) had lower ERBB2 probe signal than the highest of the ERBB2-low/
negative samples. In both cases, despite the limited sample size, the
correlations between probe signals and ER or ERBB2 status were highTable 3. Scores for Biologic and Technical Variables Used to Evaluate Sample Partitioning.Score −3 −2 −1 1 2 3Variables of smears
(1) Cellularity low Intermediate high
(2) Nuclear grade
(1) Stromal cells no yes
(2) Inflammatory cellsVariables of histologic samples
Mitoses/10 high-over field 0-9 10-19 20-50
ER or PgR (%) 0 1-19 20-39 40-59 60-79 80-100
Ki67 (%) 0-19 20-39 40-60
HER2 score 0 1+ 3+Technical variables
(1) Average signal rank 1-2 3-4 5-6 7-8 9-10 11-12
(2) Detected genes rank
Bioanalyzer RIN number <5 5-6 — 6-7 7-8 >8
Spectrophotometer
cRNA yield (ng/μl)<150 150-299 300-449 450-599 600-749 >750global gene expression. Each branch of the hierarchical tree is
bootstrapped data. The heat map below the tree reports, for each
A samples (top, four rows), surgical specimens (middle, six rows),
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relation = 0.98 and 0.89 for ER and ERBB2, respectively; P < .0001
and statistical power of 100% in both cases).
To evaluate tumor grade, we mapped on Illumina arrays the genes
of the Genomic Grade signature originally developed by Sotiriou et al.
[25] on Affymetrix arrays. We then used the original algorithm for
genomic grade calculation on the FNA leftover samples: genomic
and pathologic grade do not overlap completely but show a good cor-
relation (Pearson correlation = 0.69, P < .001, statistical power =
98.67%), with grade 2 samples subdivided in genomic grade 1–likeand genomic grade 3–like (Figure 5C ). We then assessed the possi-
bility of measuring the proliferative status of the tumor by analyzing
correlation between Ki67 levels in the surgical specimens and aver-
age expression in the FNA leftovers of 53 proliferation genes
extracted from two previous works defining breast cancer prolif-
eration signatures [26,27]. Performances of such a proliferation sig-
nature were first assessed in an aggregated Affymetrix data set of
202 samples annotated with Ki67 status, with good results (Fig-
ure W3, A and B). On FNA leftovers, as shown in Figure 5D, the
proliferation signature score was strongly correlated with Ki67
(Pearson correlation = 0.87, P < .0001, statistical power = 100%;
Figure W3C ). Interestingly, in no case did a sample with more than
30% Ki67-positive cells have a signature score lower than any sample
with less than 30% positive cells.Discussion
In this study, we showed that the leftover, residual material from
the smearing procedures of FNA samples, contains an important
source of fresh cells, suitable for banking and appropriate for mol-
ecular analysis of small nonpalpable breast lesions. Our results
demonstrate that RNA can be successfully extracted from the
FNA leftovers. RNA was of good quality and quantity and allowed
high-throughput molecular analysis procedures, such as gene
expression profiling. Importantly, no technical factors were respon-
sible for major biases in the analysis, as demonstrated by the fact that
samples subjected to global gene expression analysis were clustered
into biologically meaningful groups by their gene expression profile.
Conversely, when technical variables were considered, a totally dif-
ferent clustering was observed with no clear correlation with the
expression profile.
Most of the standardized molecular methods for measuring gene
expression require either fresh or frozen tissues. Therefore, they pose
major technical issues in timing, quantity, and quality of the material
obtained from the sampling procedure. The timing issue has already
been considered by Wong et al. [28] as a confounding factor in
microarray data analysis because of the activation and increase of
FOS hypoxia-related genes induced by ischemia of tissues taken from
postoperative specimens compared with those obtained from in vivoFigure 5. Use ofmicroarray data to classify FNA leftover samples for
ER status, HER2 status, grade, and proliferation. (A) Waterfall plot of
microarray-based measurement of ESR1 gene expression on left-
over samples, each annotated with the percent of ER-positive cells
in IHC analysis of the respective surgical samples (x axis). (B) Water-
fall plot of microarray-based measurement of ERBB2 gene expres-
sion on leftover samples, subdivided in HER2 score 3 (black bars),
score 1 (gray bars), and Score 0 (white bars) based on IHC analysis of
the respective surgical samples. (C) Waterfall plot of microarray-
basedmeasurement of the genomic grade on leftover samples, sub-
divided in histologic grade 3 (black bars), grade 2 (gray bars), and
grade 1 (white bars) subgroups based on histologic grade assess-
ments on the respective surgical samples. (D) Waterfall plot of
microarray-based measurement of the 53-gene proliferation signa-
ture score on leftover samples, subdivided in three subgroups based
on IHC analysis of the fraction of Ki67-positive cells in the respective
surgical samples: more than 30% positive cells (black bars), 15% to
30% positive cells (gray bars), and less than 15% positive cells
(white bars).
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proposed here allows to obtain adequate samples even from non-
palpable, mammographically detected lesions, which are typically not
suitable for tissue banking and therefore must be entirely formalin fixed
and paraffin embedded for adequate histologic diagnosis. These results
are consistent with previous findings [5–8,10,11,24] reporting feasibil-
ity and reliability of RNA extraction from cytologic samples of breast
cancer. However, in those studies, additional passes were performed to
retrieve material to be specifically used for molecular analysis [5–
8,10,11]. This may constitute a bias particularly when dealing with
small nonpalpable lesions because the adequacy of the sampling in cor-
rect targeting of the lesion was not taken into account. The issue of
adequacy of the material subjected to molecular analyses is of para-
mount importance. In routine practice, a significant proportion of
molecular tests performed on histologic tissue samples is not successful
either because of underrepresentation of the cancer cells (focal tumor
area in the sample with high amount of sclerosis) or because of incorrect
sampling of the tumor area (no cancer cells in the sample). The onsite
interpretation of the smears, currently performed in our protocol, guar-
antees a direct correlation with the imaging pattern and adequacy of
both cytologic and molecular samples. In this study, we managed to
obtain both diagnostic cells (from the smears) and tissue material ded-
icated to ancillary analyses (from the sample leftover) by exploiting a
single FNA procedure in 92% of cases.
These results are even more appealing in light of a possible role of
such molecular tests in guiding therapeutic decisions. A previous
study by Gong et al. [24] has shown that the amount of ESR1 and
HER2 mRNA as measured by the Affymetrix GeneChip reliably and
reproducibly establish ER status and HER2 status, in different tissue
samples including FNA. Here we show that, by using FNA leftovers,
it is possible to accurately assess ER and HER2 expression by Illumina
Gene Chip. Indeed, a good correlation with the IHC data assessed
on surgical specimens derived from the same lesion was obtained.
Although we are cautious because of the limited sample size, we
observe that these results seem even better than those obtained with
the respective Affymetrix probe sets in two cohorts of published data
sets of 1605 samples for ER status and 655 samples for ERBB2 status,
respectively (Figures W1 and W2). In addition, we successfully devel-
oped a multiprobe genomic signature for proliferation genes, finding
very high correlation with the Ki67 status, and adapted to Illumina
arrays the genomic grade index, with results that are fully compatible
with those originally observed by Sotiriou et al. [25] on Affymetrix
arrays. At present, these analyses are not requested by oncologist for
routine management of breast cancer patients; however, they could be
usefully applied to better define uncertain or borderline IHC results.
Moreover, one should note that this analysis opens the door for the
evaluation of biomarkers other than ER or HER2 that may be dem-
onstrated as associated with sensitivity or resistance to different types
of therapy.
In conclusion, our findings clearly show that cells residual from
diagnostic FNA can be successfully used for RNA extraction and
tumor banking of small nonpalpable breast cancer lesions. Most
importantly, gene expression profiling of these residual cells reliably
recapitulate the biology of the tumor specimen. Onsite adequacy
assessment of FNA sampling ensures the correct targeting of the
lesions both for cytologic and molecular analysis. This approach
may be of particular interest if applied to FNA of abdominal or
thoracic lesions, which are sampled under computed tomography
and may need precise molecular test for target therapy.Acknowledgments
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Supplementary Methods
In Silico Analysis of ESR1 Expression in Breast Cancer
For microarray-based assessment of ER status, we used expression
of the ESR1 gene measured by the Affymetrix probe set 205225_at,
as previously suggested by Gong et al. [1]. An aggregated data set of
1605 ER status–annotated samples was generated by merging six
published data sets [2–7].
Before plotting and receiver operating characteristic (ROC) curve
analysis, the Log(2) signal for the probe set of choice was scaled based
on the average signal of all probe sets included in a cross-mapping
table generated by the Microarray Quality Control Consortium [8].In Silico Analysis of HER2 Expression in Breast Cancer
For microarray-based assessment of HER2 status, we used the
expression of the ERBB2 gene measured by the Affymetrix probe
set 216836_s_at, as previously suggested by Gong et al. [1]. An
aggregated data set of 655 samples annotated for HER2 status was
generated by merging three published data sets [2,4,7]. Probe signal
scaling was performed as described above for ESR1 analysis.Genomic Grade Analysis
For microarray-based definition of the tumor grade in the FNA
leftover samples, we applied the genomic grade signature published
by Sotiriou et al. [5]. For our analysis, we mapped the genes of
genomic grade signature, originally built on the Affymetrix platform,
on the Illumina platform, using the above-mentioned MAQC table
to obtain a set of genes reproducibly measured in different micro-
array platforms. The genomic grade index was then calculated for
each of the 23 FNA leftovers as the difference between the sum of
expression of genes associated to histologic grade 3 and the sum of
expression of genes associated to histologic grade 1.Definition and Validation of a Genomic
Proliferation Signature
To build a microarray-based multigene classifier reflecting the
proliferative status of the tumor, we built a “proliferation score” by
averaging the Log(2) expression values of a set of 53 genes whose
expression is positively correlated to cell proliferation, extracted from
two published works [9,10]. The performance of this set of genes was
evaluated by a ROC curve in a data set of 202 breast cancer sam-
ples [4] annotated for Ki67 status (area under the curve = 0.824;
Figure W3B). The mean gene expression of the proliferation gene
signature was then validated on the 23 FNA leftovers subdivided inthree subgroups: high proliferation (more than 30% Ki67-positive
cells), intermediate (15%-30% positive cells), and low proliferation
(<15% positive cells), as shown in Figure 5D. An additional analysis
of correlation with the fraction of Ki67-positive cells was performed
using linear regression (Figure W3C ). In the FNA leftovers data set,
we also controlled the performance of the single probe measuring
expression of the MKI67 gene, which showed worse correlation with
the percentage of Ki67-positive cells (Pearson = 0.46 for the MKI67
gene and 0.76 for the 53-gene proliferation signature).References
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Figure W2. ERBB2 expression measured by Affymetrix probe set
in an aggregated data set of 655 published samples. (A) Waterfall
plot of ERBB2 expression in samples annotated as ERBB2-positive
(red) and ERBB2-negative (blue). (B) ROC curve analysis to evalu-
ate sensitivity and specificity of the ERBB2 Affymetrix probe set in
detecting ERBB2-positive versus ERBB2-negative samples.
Figure W3. The 53-gene proliferation signature measured in an
aggregated Affymetrix data set of 205 published samples and in
23 FNA leftovers samples. (A) Waterfall plot proliferation signature
score in samples annotated as Ki67-positive (red) and Ki67-negative
(blue). (B) ROC curve analysis to evaluate sensitivity and specificity
of the proliferation signature score in detecting Ki67-positive versus
-negative samples in the same data set. (C) Dot plot comparing,
in FNA leftovers, the proliferation signature score (x axis) with
the Ki67 score (percent positive cells, y axis) measured on the
respective surgical specimens. The R2 value of 0.7568 corresponds
to a Pearson correlation of 0.87.
